>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
89SrCl2联合唑来膦酸治疗前列腺癌骨转移的临床疗效与安全性观察
作者:梁坤  戴儒奇 
单位:海南省人民医院 核医学科, 海南 海口 570311
关键词:氯化锶 唑来膦酸 锝-99-亚甲基二膦酸盐 前列腺癌 骨转移 
分类号:R815
出版年·卷·期(页码):2017·36·第一期(82-85)
摘要:

目的:观察氯化锶(89SrCl2)联合唑来膦酸治疗前列腺癌骨转移的临床效果与安全性。方法:选择183例前列腺癌骨转移伴骨痛病例,随机分为89SrCl2联合唑来膦酸组(A组,68例)、89SrCl2联合锝-99-亚甲基二膦酸盐(99Tc-MDP)组(B组,64例)及99Tc-MDP组(C组,51例),观察各组缓解骨痛、骨转移、生活质量改善和不良反应情况。结果:治疗后A组骨痛缓解有效率(88.23%)高于B组(75.00%,P=0.049)和C组(68.63%,P=0.008);A组骨转移减少率为48.53%,高于C组(29.41%,P=0.035);A组生活质量改善率为61.76%,高于C组(41.18%,P=0.004);B组和C组的骨痛缓解有效率、骨转移减少率、生活质量比较,差异均无统计学意义;3组不良反应比较,差异无统计学意义。结论:89SrCl2联合唑来膦酸治疗前列腺癌骨转移在骨痛缓解、骨转移减少及生活质量改善等方面均优于89SrCl2,较89SrCl2联合99Tc-MDP治疗方式简捷,安全性良好,值得临床推广。

Objective:To observe the clinical efficacy and safety of 89 SrCl2combined with zoledronic in treatment of prostate cancer with bone metastasis.Methods:One hundred and eighty-three cases of prostate cancer with bone metastasis were randomly divided into 3 groups:89SrCl2 combined with zoledronic acid group (group A,68 cases), 89SrCl2 combined with99Tc-MDP group (group B,64 cases) and 89SrCl2 alone group (group C,51 cases).The occurrence of bone pain,bone metastasis,quality of life improvement and adverse reactions of the 3 groups were observed.Results:After treatment,the remission rate of bone pain ingroup A (88.23%) was higher than that in group B (75.00%,P=0.049) and group C (68.63%,P=0.008).The reduction rate of bone metastasis in group A was 48.53%,significantly higher than that in group C (29.41%,P=0.035);the quality of life improved rate in group A was 61.76%,significantly higher than that in group C (41.18%,P=0.004);there were no statistically significant differences for the remission rate of bone pain,rate of decrease of bone metastasis,and quality of life improvement between the group B and group C and there was no significant difference in the adverse reactions in the 3 groups.Conclusion:89SrCl2 combined with zoledronic acid therapy can relieve bone pain and bone metastasis,and improve quality of life without additional adverse reactions,and it's worth clinical promotion.

参考文献:

[1] 邱镜丹,李荣,王建东,等.唑来膦酸在乳腺癌中抗肿瘤作用的研究进展[J].解放军医学院学报,2015,36(6):634-636,643.
[2] 张青菊,徐文贵,戴东,等.89SrCl2联合唑来膦酸治疗骨转移瘤骨痛的安全性及疗效评价[J].中国肿瘤临床,2015,42(23):1138-1142.
[3] KURODA I.Effective use of strontium-89 in osseous metastases[J].Ann Nucl Med,2012,26(3):197-206.
[4] YANG L,DU S.Efficacy and safety of zoledronic acid and pamidronate disodium in the treatment of malignant skeletal metastasis:a metaanalysis[J].Medicine (Baltimore),2015,94(42):e1822.
[5] 刘恒超,李卫鹏,申勇,等.89SrCl2联合99Tc-MDP对乳腺癌骨转移骨痛治疗疗效[J].中国肿瘤临床,2015,42(5):297-301.
[6] 董占飞,秦永德,王新华,等.89SrCl2联合99Tc-MDP或唑来膦酸治疗肺癌骨转移疼痛的临床疗效观察[J].中国肿瘤临床,2012,39(21):1660-1662.
[7] JACOBS C,KUCHUK I,BOUGANIM N,et al.A randomized,double-blind,phaseⅡ,exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer[J].Breast Cancer Res Treat,2016,155(1):77-84.
[8] ORY B,BAUD'HUIN M,VERRECCHIA F,et al.Blocking HSP90 addiction inhibits tumor cell proliferation,metastasis development,and synergistically acts with zoledronic acid to delay osteosarcoma progression[J].Clin Cancer Res,2016,22(10):2520-2533.
[9] NISHIZAWA S,INAGAKI T,IBA A,et al.Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade[J].Springerplus,2014,3(5):586.
[10] 蒋亮,刘春辉,许斌,等.miR-146a通过抑制ROCK 1基因的表达促进去势抵抗性前列腺癌细胞的凋亡[J].东南大学学报:医学版,2015,34(3):357-360.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405549 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364